news
Scientists uncover new therapeutic target for treating colorectal tumours
New study has demonstrated that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumour growth.
List view / Grid view
Technology
news
Using computational modelling to gain insights into flu viruses
Scientists at the University of Pittsburgh have been using computational modelling to understand the body’s immune responses to avian flu.
news
Soft nickases could be the future of safe, effective gene editing
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.
news
Dissolving implant device relieves pain without drugs
Researchers have created a new implant device has the potential to provide an alternative to opioids and other highly addictive drugs.
article
Chiral nanostructures could help accelerate drug discovery
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
article
The promise of cell therapy: scaling up a new treatment paradigm for hearing loss
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
article
Challenges and opportunities: lessons learned in developing potential gene therapy cures
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
article
Leveraging a dual technology platform to develop gene therapies for a range of rare diseases
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
article
Spatial biology is the next life science revolution
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
article
Drug Target Review Screening ebook
This ebook features insights into the discovery of a new non-linear chiroptical effect for characterising nanohelices in miniscule volumes, and a novel organoid drug-screening platform with numerous eco benefits.
article
Drug Target Review Cell & Gene Therapy ebook
This ebook features articles from gene therapy specialists that look at current platforms as well as the future of promising modalities for gene therapies. It also tackles novel stem cell technology considerations and gives insight into the careful balancing act between efficacy and safety in gene therapy.
news
Novel method for early disease detection using DNA droplets
Researchers have developed a computational DNA droplet with the ability to recognise specific combinations of chemically synthesised microRNAs that act as biomarkers of tumours.
news
Novel process revolutionises microfluidic fabrication
Researchers have implemented structural colour printing in microfluidic fabrication which creates new pathways for medical diagnostics and miniaturised sensors.
news
A novel tool for studying autoimmune diseases related to COVID-19
Researchers have developed a new bioinformatics pipeline that could help investigate the mechanism underlying the development of autoimmune diseases following SARS-CoV-2 infection.
news
Resistance-proof drugs could transform treatments for viral diseases
Researchers have developed a novel class of therapeutics, called feedback disruptors, that could have the potential to be resistance-proof drugs.
